Sharemaestro Newsreel

AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed

In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie …

1% Undervalued? DENTSPLY SIRONA (XRAY) As Earnings Test Its Recovery Story

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Earnings trigger and recent business updates DENTSPLY SIRONA (XRAY) is in focus after reporting second quarter 2026 earnings on 6 August, alongside reaffirmed full year …

Novo Nordisk Stock Rises After GLP-1 Antitrust Win

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge threw out an antitrust lawsuit against Novo and Eli Lilly (NYSE:LLY). According to Reuters, …

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound

Key Points Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. There are several other reasons to consider the stock, despite the potential headwinds ahead. 10 stocks we like better than Pfizer › The past few years have been …

Roche Stock Jumps as Morgan Stanley Sees Drug Breakout

This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. …

Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of …

What Do Boston Scientific (BSX) Recalls Mean For Device Safety And Clinical Use?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Boston Scientific (NYSE: BSX) has initiated multiple product recalls covering cardiac ablation generators and vascular access sheaths due to labeling discrepancies and air …

Pfizer Inc (PFE) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

DENTSPLY SIRONA Inc. XRAY reported second-quarter 2026 adjusted earnings per share (EPS) of 52 cents, down 1.6% year over year on an actual-value basis. The bottom line beat the Zacks Consensus Estimate of 36 cents by 44.4%. GAAP EPS in the quarter was 18 …

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics DNLI reported a second-quarter 2026 loss of 68 cents per share, narrower than the Zacks Consensus Estimate of a loss of 73 cents. The company incurred a loss of 72 cents in the year-ago quarter. In late March, Denali secured a major …

Will Pharma and Specialty Demand Boost Cardinal Health's Q4 Results?

Cardinal Health CAH is scheduled to report fourth-quarter fiscal 2027 results on Aug. 11, before market open. The Zacks Consensus Estimate for sales is pegged at $65.61 billion, implying 9.1% year-over-year growth. The bottom line estimate is pinned at $2.42, suggesting growth of 16.4%. …

NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised

Novavax NVAX incurred a loss of 32 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 36 cents. In the year-ago quarter, the company had recorded earnings per share (EPS) of 62 cents, driven …

Henry Schein Inc (HSIC) Aktuelle Aktien-News

BioMarin Pharmaceutical Inc (BMRN) Aktuelle Aktien-News

Die Boston Scientific Corporation (NYSE:BSX) hat soeben ihre Ergebnisse veröffentlicht, und Analysten haben ein Kursziel von 62,69 US-Dollar festgelegt.

IDEXX Laboratories Inc (IDXX) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Eckert & Ziegler SE: Konsensus der Analysten und Kursziel | 565970 | DE0005659700

Boston Scientific Corp (BSX) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Clinical Visits Keep Falling. IDEXX Laboratories’ Q2 Earnings Report Say That Doesn’t Matter.

Fresenius Medical Care AG: Ergebnis verfehlt Analystenschätzungen: Das prognostizieren Analysten jetzt

CVS Health Stock Slips 5% Despite Beating Quarterly Estimates and Raising Annual Guidance

Dentsply Sirona Q2 2026: Umsatz sinkt, GAAP-Margen erholen sich

DENTSPLY SIRONA Inc. legt Ergebnisse für das zweite Quartal und das erste Halbjahr bis zum 30. Juni 2026 vor

DENTSPLY SIRONA Inc. bekräftigt Gewinnprognose für das Jahr 2026

Becton Dickinson hebt Gewinnprognose für das Gesamtjahr an, nachdem Ergebnisse des dritten Quartals die Erwartungen übertreffen

Zoetis Inc. passt Gewinnprognose für das Gesamtjahr 2026 an

Merck KGaA gibt Ergebnisprognose für das Jahr 2026 ab

Galenica AG bestätigt Ergebnisprognose für das Jahr 2026

Becton Dickinson Aktie steigt nach überzeugenden Quartalszahlen und angehobener Prognose

Becton, Dickinson: Bereinigter Gewinn und Umsatz im dritten Geschäftsquartal steigen; Prognose für bereinigtes EPS 2026 angehoben

Becton Dickinson übertrifft Erwartungen und hebt Prognose an

Unitedhealth Group Inc (UNH) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Dexcom Inc (DXCM) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Johnson & Johnson (JNJ) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Avantor Inc (AVTR) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

BioMarin Pharmaceutical Inc (BMRN) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen